Enanta Pharmaceuticals (ENTA) vs Pyxis Oncology (PYXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Enanta Pharmaceuticals (ENTA) has outperformed Pyxis Oncology (PYXS) over the past year, losing 40.1% versus a loss of 62.3%. Over five years, PYXS leads with a -85.9% price change compared with -91.7% for ENTA. Enanta Pharmaceuticals is the larger company by market cap ($222.2 million vs $216.5 million), about 1.0 times the size.
Enanta Pharmaceuticals converts more of its revenue into profit, with a net margin of -108.3% versus -574.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENTA | PYXS |
|---|---|---|
| Share price | $7.62 | $1.81 |
| Market cap | $222.19M | $216.49M |
| 1-day change | -4.51% | +7.74% |
| YTD return | -51.68% | +57.39% |
| 1-year return | -40.14% | -62.29% |
| 5-year return | -91.71% | -85.90% |
| EPS (TTM) | $-2.35 | $-1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $63.00M | $13.86M |
| Revenue growth (YoY) | -3.56% | -14.17% |
| Net income (latest FY) | $-68.25M | $-79.62M |
| Gross margin | — | 82.77% |
| Operating margin | -99.01% | -609.18% |
| Net margin | -108.33% | -574.55% |
| 52-week high | $17.15 | $5.55 |
| 52-week low | $7.56 | $1.03 |
| Distance from 52-week high | -55.57% | -67.39% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +186.48% | +354.14% |
| Average volume | 287.81K | 1.06M |
| Shares outstanding | 29.16M | 119.61M |
| Employees | 120 | 56 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ENTA has outperformed PYXS by 22.2 percentage points over the past year.
- Enanta Pharmaceuticals is more profitable, keeping -108.3 cents of every revenue dollar as net income versus -574.5 cents for Pyxis Oncology.
- Enanta Pharmaceuticals grew revenue faster in its latest fiscal year (-3.56% vs -14.17%).
About Enanta Pharmaceuticals
ENTA stock →Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 120 employees
About Pyxis Oncology
PYXS stock →Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
ENTA vs PYXS FAQ
Which is bigger, Enanta Pharmaceuticals or Pyxis Oncology?
Enanta Pharmaceuticals (ENTA) is larger, with a market capitalization of $222.19M compared with $216.49M for Pyxis Oncology (PYXS).
Which stock has performed better over the past year, ENTA or PYXS?
ENTA returned -40.14% over the past 12 months, compared with -62.29% for PYXS (price return, excluding dividends). Past performance does not predict future results.
Are Enanta Pharmaceuticals and Pyxis Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.